



# **Inherited Thrombocytopenia and Thrombasthenia Among Egyptian Children and Adolescents with Un-Diagnosed Bleeding or Mis-Diagnosed as ITP**

Thesis

*Submitted in Partial Fulfillment of Doctorate Degree  
in Pediatrics*

Presented By

**Marwa Waheed Abd El Aal Tolba**

Under Supervision of

**Prof. Mohsen Saleh Elalfy**

*Professor of pediatrics*

*Faculty of Medicine - Ain Shams University*

**Prof. Azza Abd El Gawad Tantawy**

*Professor of Pediatrics*

*Faculty of Medicine - Ain Shams University*

**Prof. Mohammad Tarif Hamza**

*Assistant Professor of Clinical Pathology*

*Faculty of Medicine - Ain Shams University*

**Dr. Marwa Mohammad Reda**

*Lecturer of Pediatrics*

*Faculty of Medicine - Ain Shams University*

**Dr. Iman Abdel Rahman Ismail**

*Consultant of Clinical Pathology*

*Faculty of Medicine - Ain Shams University*

*Faculty of Medicine*

*Ain Shams University*

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿وَعَلَّمَكَ مَا لَمْ تَكُنْ تَعْلَمُ وَكَانَ

فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا﴾

صدق الله العظيم  
سورة النساء آية (١١٣)

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Mohsen Saleh Elalfy**, Professor of Pediatrics, Faculty of Medicine - Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Azza Abd El Gawad Tantaawy**, Professor of Pediatrics Faculty of Medicine - Ain Shams University, for her kind care, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Iman Ragab**, Assistant Professor of Pediatrics Faculty of Medicine - Ain Shams University, for her great help, active participation, supervision and guidance.*

*I am profoundly grateful to **Prof. Mohammad Tarif Hamza**, Assistant Professor of Clinical Pathology Faculty of Medicine - Ain Shams University, for his guidance and cooperation in this work.*

*I wish to introduce my deep respect and thanks to **Dr. Iman Abdel Rahman Ismail**, Consultant of Clinical Pathology Faculty of Medicine - Ain Shams University.*

*Maruwa Waheed Abd El Aal Tolba*

## Dedication

*Words can never express my sincere thanks to **My Family** especially **My Mother** for their generous emotional support and continuous encouragement, which brought the best out of me. I owe them all every achievement throughout my life.*

*I would like to express my everlasting gratitude to all **My Professors, Colleagues and Friends** with very special thanks to my dearest **Salwa Mostafa**, whose support through all these years was endlessly. Special thanks to my friend **Nihal Hussein** my work partner and dear friend.*

*I would like also to thank the **Patients** who agreed willingly to be part of my study and without them; I would not have been able to accomplish this work.*

# *List of Contents*

Title	Page No.
List of Abbreviations .....	6
List of Tables .....	7
List of Figures .....	8
Abstract .....	10
Introduction .....	1
Aim of the Study .....	12
Review of Literature	
▪ Thrombocytopenia .....	13
▪ Thrombasthenia .....	26
▪ Diagnostic Approach to a Child with Bleeding Tendency .....	35
Subjects and Methods .....	46
Results .....	55
Discussion .....	72
Conclusion .....	83
Recommendations .....	84
Summary .....	85
Limitations of the Study .....	90
References .....	91
Arabic Summary .....	—

## *List of Abbreviations*

Abb.	Full term
ADP.....	Adenosine 5'-diphosphate
ARC .....	Arthyrogryposis, renal dysfunction and cholestasis
CAMT .....	Congenital amegakaryocytic thrombocytopenia
CD .....	Cluster of differentiation
DITP .....	Drug-induced immune thrombocytopenia
Gp.....	Glycoprotein
GT .....	Glanzmann`s thrombasthenia
HOX .....	Homeobox
ITP .....	Idiopathic thrombocytopenia
IVIG .....	Intravenous immunoglobulins
MEP .....	Megakaryocyte-erythroid progenitor
MK-BFU.....	Megakaryocyte burst forming unit
MK-CFU.....	Megakaryocyte colony forming unit
MPL .....	Myeloproliferative
MPV .....	Mean platelet volume
NR.....	Platelet count lower than $30 \times 10^9/L$ or less than doubling of the baseline count
PCR.....	Polymerase chain reaction
PRBCS.....	Packed red blood cells
QPD .....	Quebec platelet disorder
R.....	Platelet count between 30 and $100 \times 10^9/L$ and at least doubling of the baseline count
TAR.....	Thrombocytopenia absent radii
TPO.....	Thrombopoietin
TxA <sub>2</sub> .....	Thromboxane A <sub>2</sub>
VWF .....	Von Willebrand factor
WAS .....	Wiskott–Aldrich syndrome

## *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Inherited thrombocytopenias classified by platelet size. ....	17
<b>Table (2):</b>	Different aggregation responses in patients with thrombocytopathies. ....	41
<b>Table (3):</b>	Inherited platelet membrane glycoprotein disorders. ....	43
<b>Table (4):</b>	Demographic data of studied groups I and II.....	55
<b>Table (5):</b>	Demographic data subgroup IA & IB.....	57
<b>Table (6):</b>	SMOG score and bleeding severity groups I and II. ....	58
<b>Table (7):</b>	Primary level of investigations of studied groups I and II. ....	62
<b>Table (8):</b>	Primary level of investigation, platelet indices of studied subgroups I (A) and I (B). ....	64
<b>Table (9):</b>	Secondary level of investigations, surface platelet glycoprotein cluster of differentiation (CD) markers of studied groups I and II.....	66
<b>Table (10):</b>	Secondary level of investigation, platelet surface glycoproteins of studied subgroups I (A) and I (B).....	67
<b>Table (11):</b>	Secondary level of investigation, platelet surface glycoprotein cluster of differentiation (CD) markers of studied subgroup I (C). ....	68
<b>Table (12):</b>	Correlation between bleeding severity and platelet surface glycoproteins, cluster of differentiation (CD) markers among studied groups. ....	69

## *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Shows the essential developmental steps of megakaryocytes, from a pluripotent stem cell to a fully differentiated, polyploid, platelet-shedding cell .....	13
<b>Figure (2):</b>	Passive transport of platelets and chemicals in healthy blood vessels (left); reactions happening in case of vessel wall injury that leads to the formation of a platelet plug (right).....	14
<b>Figure (3):</b>	Real-time and confocal visualization of platelet adhesion .....	15
<b>Figure (4):</b>	Platelet appearances associated with mutations in genes causing Inherited thrombocytopenia.....	40
<b>Figure (5):</b>	Shows different Genetic approaches used for discovering the molecular defects responsible for the known forms of inherited thrombocytopenias.....	45
<b>Figure (6):</b>	Male and female ratios of the studied groups. ....	56
<b>Figure (7):</b>	Showed bleeding severity in different groups. ....	59
<b>Figure (8):</b>	Showed percentages of different diagnoses reached in subgroup I(B). ....	59
<b>Figure (9):</b>	Showed percentages of different diagnoses reached in Group II.....	60
<b>Figure (10):</b>	Roc curve analysis revealed that the cut off of MPV $\leq 13.9$ fl could be diagnostic for ITP patients with sensitivity 100% and specificity 85.7%. ....	65



## *List of Figures Cont...*

Fig. No.	Title	Page No.
<b>Figure (11):</b>	Electron microscopic appearance of platelets in a patient with gray platelet syndrome.....	71
<b>Figure (12):</b>	Blood film showing leucocyte inclusions in a patient with Chediak-Higashi syndrome. ....	71

### Abstract

**Background:** Childhood hereditary thrombocytopathies are an undiagnosed group of disorders that are mis-attributed to immunological etiology. In this study we aimed at identifying misdiagnosed cases of hereditary thrombocytopenia and thrombasthenia.

**Patients and methods:** This cross sectional study included 67 patients with chronic thrombocytopenia and undiagnosed bleeding followed at Ain Shams University pediatrics hematology clinic. They were divided into; group I (n=47) with low platelet count and group II (n=20) with normal platelet count. Diagnostic approach was applied consisting of primary level of investigations included complete blood counts (CBC) with mean platelet volume (MPV) and light microscopic study of platelet morphology and granules and white blood cell count (WBCs) granules. Secondary level of investigations included flow cytometric analysis for platelet surface glyco-proteins, Tertiary level of investigations included bone marrow aspirate, electron microscope and genetic study when required.

**Results:** 25% of the patients were diagnosed as inherited thrombocytopenia and 25% as thrombasthenia. Probable diagnosis was reached in 34 patients (50.7%). Platelet glycoproteins diagnosed 24 patients (16 patients (23.9%) as Glanzmann's thrombasthenia, 7 patients (10.4%) as Bernard Soulier syndrome and 1 patient (1.5 %) was diagnosed as collagen receptor defect with no significant correlation with their bleeding severity. Genetic testing confirmed diagnosis of 6 patients (4 patients (5.9%) as congenital amegakaryocytic thrombocytopenia (CAMT), 2 patients (3%) as Wiskott Aldrich syndrome).

**Conclusion:** Applying a diagnostic approach showed the importance of platelet glycoproteins and targeted gene testing in identifying the underdiagnosed cases of hereditary thrombocytopenia and thrombasthenia.

**Keywords:** Idiopathic thrombocytopenia, wiskott-aldrich syndrome, mean platelet volume

## INTRODUCTION

**I**diopathic thrombocytopenia (ITP) is considered one of the most common encountered causes of low platelet count occurring in approximately 1 in 10,000 of the general population (*ElAlfy et al., 2003*).

Inherited thrombocytopenias and thrombasthenia are group of rare diseases that are often misdiagnosed as chronic idiopathic thrombocytopenia (ITP) (*Gohda et al., 2006*). An atypical clinical course should serve as a red flag and be followed by proper studies to exclude heritable conditions (*Picu et al., 2005*).

Diagnosing inherited thrombocytopenias will not just prevent unnecessary treatment to this group of patients (when treated as ITP), but will also allows detecting patients at risk of developing additional disorders more dangerous than thrombocytopenia itself during life (*Noris and Pecci, 2017*).

Developing a systematic approach for diagnosis of bleeding disorders and identifying the underlying etiology in patients with chronic ITP as well as other cases with bleeding tendency despite normal platelet count and normal coagulation profile is challenging (*D'Andrea et al., 2009*).

## **AIM OF THE STUDY**

**T**o detect inherited thrombocytopenias and or thrombasthenia with low platelet count in patients diagnosed with persistent or chronic ITP with no response to immune-modulatory therapy as well as studying patients with unexplained bleeding disorders with normal platelet number and coagulation profile.


## Chapter 1

# THROMBOCYTOPENIA

## Introduction

### Thrombopoiesis:

Platelet counts range from 150000 to 400000 cell per microliter, however, it is normally kept within a narrow range for every person, This is done by a balance between thrombopoiesis, which is primarily regulated by thrombopoietin (TPO), and platelet consumption (*Johnson et al., 2016*).




**Figure (1):** Shows the essential developmental steps of megakaryocytes, from a pluripotent stem cell to a fully differentiated, polyploid, platelet-shedding cell, MK: megakaryocytes, BFU: burst forming unit, CFU: colony forming unit (*Drachman, 2004*).

Hematopoietic stem cells have the capacity to proliferate; self renew, and differentiate into cells of all the blood lineages

to maintain hematopoiesis. Megakaryocytes are derived from the megakaryocyte-erythroid progenitor (MEP), that gives rise to cells of both megakaryocytic and erythroid lineages and controlled by many transcription factors, including GATA-binding factor 1 (GATA-1) (*Fan et al., 2017*).

The average human platelet life span is 7–10 days. After they are formed from bone marrow megakaryocytes, platelets are divided into two compartments: (1) the stationary compartment in the spleen accounting for about one third of the whole platelet mass and (2) circulating platelets representing the remaining two thirds. The final platelet count in the peripheral blood is the result of platelet production, distribution into the two compartments, consumption due to adhesion to vessel wall damage or formation of platelet aggregates, and clearance (*Bakchoul and Schulze, 2016*).




**Figure (2):** Passive transport of platelets and chemicals in healthy blood vessels (left); reactions happening in case of vessel wall injury that leads to the formation of a platelet plug (right) (*Storti et al., 2014*).

### **Platelets plug formation:**

Platelets plug formation passes into main four phases; adhesion of platelet glycoprotein (Gp) 1b receptor to

subendothelium, vasoconstriction which is mediated by activated platelets producing thromboxane A<sub>2</sub> (TxA<sub>2</sub>), swelling and inter-platelet binding by fibrinogen cross links to GpIIb/IIIa receptors on platelet membrane, and maturation in which fibrinogen converts to fibrin with cross-linking to increase the strength of the plug (*Galioto et al., 2011*).



**Figure (3):** Real-time and confocal visualization of platelet adhesion. (a) Series of still images from video recordings of platelet adhesion and spreading on fibrinogen under flow (DIC), shear rate 100/s. (b) Still images taken from live recordings of platelet thrombus formation (arrow head) on a collagen surface, shear rate 1600/s. (c) Confocal images after whole blood perfusion over fibrinogen, immunolabeling with anti-GPIb or anti-CD63 antibody (inset). (d) Confocal image after whole blood perfusion over collagen; immunolabeling with anti-GPIb antibody (*Heijnen and Korporaal, 2017*).